Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    NIAID | Open Studies | Exclude Unknown | Hepatitis C
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Staged Phase I/II Hepatitis C Prophylactic Vaccine
Condition: Hepatitis C
Interventions: Other: Placebo;   Biological: AdCh3NSmut1;   Biological: MVA-NSmut
2 Recruiting Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Conditions: Hepatitis;   HIV;   Liver Cancer
Intervention:
3 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
4 Recruiting Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre or Post Liver Transplant
Conditions: HIV;   Hepatitis C;   Cirrhosis
Intervention: Drug: Harvoni
5 Recruiting 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Conditions: HIV-1 Infection;   Hepatitis C
Interventions: Drug: Ledipasvir/sofosbuvir;   Drug: Ribavirin
6 Recruiting Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
Condition: Hepatitis C
Intervention: Drug: Zoster vaccine live
7 Recruiting Effects of Persistent Innate Immune Activation on Vaccine Efficacy
Condition: Hepatitis C Infection
Intervention: Drug: Recombivax
8 Recruiting Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Conditions: HIV-1 Infection;   Hepatitis
Interventions: Drug: Ribavirin;   Drug: Sofosbuvir;   Drug: Ledipasvir/Sofosbuvir

Indicates status has not been verified in more than two years